• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

10-乙基-10-脱氮氨基蝶呤在大鼠和犬体内的毒性、消除及代谢

Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs.

作者信息

Fanucchi M P, Kinahan J J, Samuels L L, Hancock C, Chou T C, Niedzwiecki D, Farag F, Vidal P M, DeGraw J I, Sternberg S S

出版信息

Cancer Res. 1987 May 1;47(9):2334-9.

PMID:2436760
Abstract

10-Ethyl-10-deazaaminopterin (10-EdAM) is an antifolate compound with greater therapeutic activity than methotrexate against transplanted tumors in mice. When given weekly for 3 weeks, the 10% lethal dose in rats was 125 mg/kg (i.p.) and in dogs it was 2.5 mg/kg (i.v.). The major histopathological findings in intoxicated animals were damage to the mucosa of the gastrointestinal tract in rats and dogs and hypocellularity of the marrow in rats. The elimination of 50 mg/kg of 10-EdAM from the plasma of rats was triexponential with a terminal phase t1/2 of 18.5 h but a mean residence time of 0.7 h. The primary route of elimination in rats was biliary secretion of parent compound and eventual excretion of the parent compound and the deglutamate metabolite in the feces; the 7-hydroxy metabolite was also present in plasma, bile, and feces. Biliary elimination was independent of dose over a 5-fold range. The elimination of 10-EdAM from the plasma of dogs was also triexponential with a mean terminal phase t1/2 of 9.1 h and a mean residence time of 2.5 h; nonrenal clearance was the primary route of elimination. The pharmacokinetic parameters were independent of dose over the range of 0.25 to 5.0 mg/kg. High tissue concentrations of 10-EdAM were observed initially in liver, kidney, and small intestine of rats, while concentrations in bone marrow were low. Some polyglutamate formation was observed in these tissues as early as 0.5 h after drug administration but declined over 72 h.

摘要

10-乙基-10-脱氮氨基蝶呤(10-EdAM)是一种抗叶酸化合物,对小鼠移植肿瘤的治疗活性比甲氨蝶呤更强。当每周给药3周时,大鼠的10%致死剂量为125毫克/千克(腹腔注射),犬的10%致死剂量为2.5毫克/千克(静脉注射)。中毒动物的主要组织病理学发现是大鼠和犬的胃肠道黏膜损伤以及大鼠的骨髓细胞减少。50毫克/千克的10-EdAM从大鼠血浆中的消除呈三指数型,终末相t1/2为18.5小时,但平均驻留时间为0.7小时。大鼠的主要消除途径是母体化合物的胆汁分泌以及母体化合物和脱谷氨酸代谢物最终经粪便排泄;7-羟基代谢物也存在于血浆、胆汁和粪便中。在5倍剂量范围内,胆汁消除与剂量无关。10-EdAM从犬血浆中的消除也呈三指数型,平均终末相t1/2为9.1小时,平均驻留时间为2.5小时;非肾清除是主要消除途径。在0.25至5.0毫克/千克的剂量范围内,药代动力学参数与剂量无关。最初在大鼠的肝脏、肾脏和小肠中观察到高组织浓度的10-EdAM,而骨髓中的浓度较低。在给药后0.5小时,这些组织中就观察到一些多聚谷氨酸的形成,但在72小时内下降。

相似文献

1
Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs.10-乙基-10-脱氮氨基蝶呤在大鼠和犬体内的毒性、消除及代谢
Cancer Res. 1987 May 1;47(9):2334-9.
2
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.10-乙基-10-脱氮氨基蝶呤在晚期癌症成年患者中的I期试验及临床药理学评估
Cancer Res. 1988 Oct 1;48(19):5573-9.
3
Fluorometric high-performance liquid chromatographic analysis of 10-deazaaminopterin, 10-ethyl-10-deazaaminopterin, and known metabolites.10-脱氮氨基蝶呤、10-乙基-10-脱氮氨基蝶呤及已知代谢物的荧光高效液相色谱分析
Anal Biochem. 1985 Oct;150(1):203-13. doi: 10.1016/0003-2697(85)90460-9.
4
Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.新型降胆固醇化合物S-8921在大鼠和犬体内的处置与代谢
Arzneimittelforschung. 1998 Oct;48(10):995-1006.
5
Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.大鼠、犬和猴单次口服给予[羰基-14C]枸橼酸莫沙必利后的吸收、分布及排泄情况。
Arzneimittelforschung. 1993 Oct;43(10):1084-94.
6
Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.L-692,429的药代动力学与处置。一种新型非肽类生长激素促分泌素在临床前物种中的研究。
Drug Metab Dispos. 1996 Jul;24(7):753-60.
7
Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.通过定量和定性代谢物谱分析对放射性标记的muraglitazar在动物和人类中的比较代谢。
Drug Metab Dispos. 2007 Jan;35(1):150-67. doi: 10.1124/dmd.106.012450. Epub 2006 Oct 24.
8
NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).1-氨基-2,4-二溴蒽醌(CAS编号:81-49-2)在F344/N大鼠和B6C3F1小鼠中的NTP毒理学与致癌性研究(饲料喂养研究)
Natl Toxicol Program Tech Rep Ser. 1996 Aug;383:1-370.
9
The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.罗非昔布(一种强效且选择性的环氧化酶-2抑制剂)在大鼠和犬体内的吸收、分布、代谢及排泄情况。
Drug Metab Dispos. 2000 Oct;28(10):1244-54.
10
Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice.甲氨蝶呤和氨基蝶呤的8-脱氮类似物在小鼠体内的细胞毒性、摄取、聚谷氨酸形成及抗白血病作用
Cancer Res. 1988 Mar 15;48(6):1481-8.

引用本文的文献

1
Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer.10-乙基-10-脱氮氨基蝶呤(依达曲沙)用于非小细胞肺癌时每周给药一次的药代动力学
Cancer Chemother Pharmacol. 1993;31(4):328-32. doi: 10.1007/BF00685680.
2
Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer.
Invest New Drugs. 1990 Aug;8(3):299-304. doi: 10.1007/BF00171841.